CNS Pharmaceuticals, Inc.
CNSP
$5.78
-$0.16-2.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.69% | 30.75% | 65.76% | -23.65% | -12.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.08% | 14.70% | 87.07% | -42.20% | -4.71% |
| Operating Income | -12.08% | -14.70% | -87.07% | 42.20% | 4.71% |
| Income Before Tax | -8.97% | -14.78% | -87.50% | 42.59% | 6.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.97% | -14.78% | -87.50% | 42.59% | 6.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.97% | -14.78% | -87.50% | 42.59% | 6.16% |
| EBIT | -12.08% | -14.70% | -87.07% | 42.20% | 4.71% |
| EBITDA | -11.66% | -14.68% | -87.09% | 42.21% | 4.72% |
| EPS Basic | 94.10% | 61.43% | 72.66% | 96.24% | -- |
| Normalized Basic EPS | 94.10% | 61.43% | 72.65% | 96.24% | -- |
| EPS Diluted | 94.08% | 61.43% | 72.66% | 96.24% | -- |
| Normalized Diluted EPS | 94.10% | 61.43% | 72.65% | 96.24% | -- |
| Average Basic Shares Outstanding | 1,747.66% | 197.62% | 585.81% | 1,427.05% | -- |
| Average Diluted Shares Outstanding | 1,747.66% | 197.62% | 585.81% | 1,427.05% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |